PRC2
生物
MHC I级
二价染色质
抗原处理
主要组织相容性复合体
免疫系统
基因沉默
细胞生物学
染色质
遗传学
组蛋白H3
染色质重塑
基因
作者
Marian L. Burr,Christina E. Sparbier,Kah Lok Chan,Yih-Chih Chan,Ariena Kersbergen,Enid Y.N. Lam,Elizabeth Azidis-Yates,Dane Vassiliadis,Charles C. Bell,Omer Gilan,Susan Jackson,Lavinia Tan,Stephen Q. Wong,Sebastian Hollizeck,Ewa M. Michalak,Hannah V. Siddle,Michael T. McCabe,Rab K. Prinjha,Glen R. Guerra,Benjamin Solomon
出处
期刊:Cancer Cell
[Cell Press]
日期:2019-09-26
卷期号:36 (4): 385-401.e8
被引量:505
标识
DOI:10.1016/j.ccell.2019.08.008
摘要
Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved function of polycomb repressive complex 2 (PRC2) that mediates coordinated transcriptional silencing of the MHC-I antigen processing pathway (MHC-I APP), promoting evasion of T cell-mediated immunity. MHC-I APP gene promoters in MHC-I low cancers harbor bivalent activating H3K4me3 and repressive H3K27me3 histone modifications, silencing basal MHC-I expression and restricting cytokine-induced upregulation. Bivalent chromatin at MHC-I APP genes is a normal developmental process active in embryonic stem cells and maintained during neural progenitor differentiation. This physiological MHC-I silencing highlights a conserved mechanism by which cancers arising from these primitive tissues exploit PRC2 activity to enable immune evasion.
科研通智能强力驱动
Strongly Powered by AbleSci AI